Faeth Therapeutics, Inc.

NasdaqCM:FTH Stock Report

Market Cap: US$891.5m

Faeth Therapeutics Management

Management criteria checks 0/4

Faeth Therapeutics' CEO is Anand Parikh, appointed in Jun 2026, has a tenure of less than a year. directly owns 3.16% of the company’s shares, worth $28.21M. The average tenure of the management team and the board of directors is 0.7 years and 0.6 years respectively.

Key information

Anand Parikh

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership3.2%
Management average tenureless than a year
Board average tenureless than a year

Recent management updates

Recent updates

Seeking Alpha • Sep 18

Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion

Summary I am initiating Faeth Therapeutics with a "Buy" rating following its acquisition, name change, and $200M private placement. Company's lead asset, PIKTOR, targets multi-node PAM pathway alterations in endometrial cancer and HR+/HER2- breast cancer, with key phase 2 and 1b/2 data catalysts ahead. Topline results for PIKTOR in 2nd-line advanced endometrial cancer are expected by year-end 2026, with interim breast cancer data in 2027. Company's cash runway is sufficient for near-term catalysts, but increased trial expenses suggest a likely need for additional funding within several months. Read the full article on Seeking Alpha
Analysis Article • Nov 03

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jul 02

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Mar 14

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Aug 14

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 09

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics press release (NASDAQ:SNSE): Q2 GAAP EPS of -$0.34 beats by $0.06. Cash, cash equivalents and marketable securities were $123.7 million as of June 30, 2022, as compared to $147.6 million as of December 31, 2021. Sensei expects its current cash balance to fund operations into the first quarter of 2025.
Analysis Article • Apr 18

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 16

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO

Anand Parikh (40 yo)

less than a year
Tenure

Mr. Anand Parikh, Esq., J.D., served as Chief Operating Officer and Director at Sensei Biotherapeutics, Inc. from February 17, 2026 and serves as its Chair since 2026 and serves as its Chief Executive Offi...

Leadership Team

NamePositionTenureCompensationOwnership
Josiah Craver
Senior VP of Finance2yrsUS$409.71k0%
$ 0
Christopher Gerry
General Counsel & Secretary4.2yrsUS$434.60k0.0037%
$ 32.9k
Anand Parikh
CEO, President & Chairless than a yearno data3.16%
$ 28.2m
Siddhartha Mukherjee
Scientific Co-Founderless than a yearno datano data
Lewis Cantley
Scientific Co-Founderless than a yearno datano data
Scott Lowe
Scientific Co-Founderless than a yearno datano data
Gregory Hannon
Scientific Co-Founderless than a yearno datano data
Karen Vousden
Scientific Co-Founder & Directorless than a yearno data0.16%
$ 1.5m
Oliver Maddocks
Co-Founder & Chief Scientific Officerless than a yearno datano data
Benjamin Hopkins
Scientific Co-Founderless than a yearno datano data
Simon Knott
Scientific Co-Founderless than a yearno datano data
Marcus Goncalves
Scientific Co-Founderless than a yearno datano data
0.7yrs
Average Tenure
55yo
Average Age

Experienced Management: FTH's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Anand Parikh
CEO, President & Chairless than a yearno data3.16%
$ 28.2m
Karen Vousden
Scientific Co-Founder & Directorno datano data0.16%
$ 1.5m
Robert Holmen
Independent Director9.7yrsUS$62.22k0.0050%
$ 44.1k
Phillip Donenberg
Independent Directorless than a yearno data0%
$ 0
Richard Ulevitch
Member of Immuno-Oncology Advisory Board5.3yrsno datano data
Robert Schreiber
Member of Immuno-Oncology Advisory Boardno datano datano data
Sona Saira Ramasastry
Directorless than a yearno datano data
Stephen Hahn
Directorless than a yearno data0.17%
$ 1.5m
Alain Algazi
Member of Immuno-Oncology Advisory Boardno datano datano data
Daniel Sterman
Member of Immuno-Oncology Advisory Boardno datano datano data
Maura Gillison
Member of Immuno-Oncology Advisory Board5.3yrsno datano data
Sara Pai
Member of Immuno-Oncology Advisory Boardno datano datano data
0.6yrs
Average Tenure
65yo
Average Age

Experienced Board: FTH's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/21 07:55
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Faeth Therapeutics, Inc. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Zhiqiang ShuBerenberg
Suranjit MukherjeeBTIG